Department of Ophthalmology and Visual Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI.
J Glaucoma. 2018 Jul;27 Suppl 1:S87-S90. doi: 10.1097/IJG.0000000000000920.
The treatment of glaucoma in exfoliation syndrome is similar to primary open-angle glaucoma. Frequently, exfoliation glaucoma (XFG) patients require early polytherapy with topical medications. Little emphasis has been placed on tailoring treatment specifically to XFG. New outflow enhancing agents with novel mechanisms of action, such as Rho Kinase inhibition, NO signaling (both recently FDA-approved drugs) and adenosine α1-receptor stimulation, act directly on the trabecular meshwork. These agents may prove to be effective in lowering intraocular pressure and perhaps altering the pathogenesis of XFG aid in the long-term management of this disease.
在剥脱综合征中,青光眼的治疗与原发性开角型青光眼相似。通常,剥脱性青光眼(XFG)患者需要早期进行局部药物联合治疗。但针对 XFG 患者,还没有特别强调制定具体的治疗方案。一些新的具有新作用机制的房水流出增强剂,如 Rho 激酶抑制、NO 信号(最近均被 FDA 批准的药物)和腺苷 α1 受体刺激,可直接作用于小梁网。这些药物可能在降低眼压方面有效,并且可能改变 XFG 的发病机制,有助于长期管理这种疾病。